Royalty Pharma plc
RPRX
Clasificación en acciones
#867
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a... Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Precio por acción
$62.21
Capitalización bursátil
$27.70B
Cambio (1 día)
3.22%
Cambio (1 año)
69.83%
País
US
Comercio Royalty Pharma plc (RPRX)
Categoría
Healthcare
Ratio P/S de Royalty Pharma plc (RPRX)
Ratio P/S al October 2026 TTM: 10.31
Según los informes financieros más recientes y el precio de las acciones de Royalty Pharma plc, el ratio P/S actual (TTM) es 10.31. Al final de 2023, el ratio P/S era 5.34.
Historial del ratio P/S de Royalty Pharma plc desde 2015 hasta 2026
Ratio P/S al final de cada año
| Año | Ratio P/S | Cambiar |
|---|---|---|
| 2026 (TTM) | 10.31 | 104.99% |
| 2024 | 5.03 | -5.87% |
| 2023 | 5.34 | -30.98% |
| 2022 | 7.74 | 7.16% |
| 2021 | 7.22 | -21.12% |
| 2020 | 9.15 | 5.36% |
| 2019 | 8.69 | -1.07% |
| 2018 | 8.78 | -10.97% |
| 2017 | 9.86 | -31.45% |
| 2016 | 14.39 | -11.98% |
| 2015 | 16.35 | 0.00% |
Ratio P/S de empresas similares o competidoras
| Empresa | Ratio P/S | Diferencia del ratio P/S | País |
|---|---|---|---|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 15.12 | 46.67% |
US
|
|
| 2.36 | -77.11% |
HK
|
